A history of early stent thrombosis is associated with prolonged clot lysis time

Summary

It has been demonstrated that formation of compact plasma fibrin clots resistant to plasmin-mediated lysis characterises patients following instent thrombosis (IST). The relationship between defective fibrinolysis, reflected as prolonged clot lysis time (CLT) and IST is unclear. We sought to investigate whether patients with acute and subacute IST have impaired fibrinolytic capacity. We studied 41 definite IST patients, including 15 with acute and 26 with subacute IST experienced 2–73 months prior to enrollment, versus 41 controls matched for demographics, cardiovascular risk factors, concomitant treatment and angiographic/stent parameters. CLT, reflecting lysis of a tissue factor-induced plasma clot by exogenous tissue plasminogen activator, together with plasminogen activator inhibitor-1 (PAI-1) antigen and activity, thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity, thrombomodulin (TM), plasminogen and α₂-antiplasmin (α₂AP) were measured. There were no inter-group differences in angiographic parameters, indication to the first PCI, culprit vessel or a type of stent. Patients with IST had 11% longer CLT (p=0.005) and 13% higher PAI-1 antigen (p=0.04) compared to controls. There were positive correlations in both groups between CLT and PAI-1 antigen and TAFI activity (all p<0.001). Multiple regression analysis showed that CLT (odds ratio [OR]=1.04 per 1 minute, 95% CI 1.01–1.08, p=0.02) and platelet count (OR=1.01 per 1,000/μl, 95% CI 1.00–1.02, p=0.034) were independent predictors of IST (R2=0.28, p<0.05). Concluding, impaired fibrinolytic potential, that is in part determined by plasma PAI-1 antigen and TAFI activity, characterises patients with a history of acute and subacute IST, which might help identify patients at higher risk of IST.

Keywords

Thrombosis - clot lysis time - hypofibrinolysis - stents

• References

• 1 Bertrand ME, Rupprecht HJ, Urban P. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624-629.
• 2 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
• 3 Motovska Z, Widimsky P, Marinov I. et al. Clopidogrel resistance “live” — The risk of stent thrombosis should be evaluated before procedures. Thromb J 2009; 07: 6.
• 4 Luscher TF, Steffel J, Eberli FR. et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058.
• 5 Orford JL, Lennon R, Melby S. et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002; 40: 1567-1572.
• 6 Park DW, Park SW, Park KH. et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
• 7 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
• 8 Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-321.
• 9 Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 05: 116-124.
• 10 Undas A, Ariëns RA. Fibrin Clot Structure and Function: A Role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
• 11 Undas A, Szuldrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2007; 196: 551-558.
• 12 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 13 Collet JP, Lesty Cl, Montalescot G. et al. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003; 41: 21331-21335.
• 14 Undas A, Celinska-Lowenhoff M, Lowenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 04: 1029-1036.
• 15 Undas A, Brozek J, Jankowski M. et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26: 1397-1404.
• 16 Undas A, Slowik A, Wolkow P. et al. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125: 357-361.
• 17 Lisman T, Leebeek FWG, Mosnier LO. et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
• 18 Meltzer ME, Lisman T, de Groot PG. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
• 19 Meltzer ME, Doggen CJ, de Groot P hG. et al. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468-77.
• 20 Undas A, Zalewski J, Krochin M. et al. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol 2010; 30: 278-282.
• 21 Cutlip DE, Windecker S, Mehran R. et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
• 22 Undas A, Wypasek E, Kapelak B. et al. Shorter preoperative fibrin clot lysis time predisposes to increased chest tube drainage in patients undergoing elective coronary artery bypass grafting surgery. Blood Coagul Fibrinolysis 2010; 21: 380-381.
• 23 Meltzer ME, Doggen CJ, de Groot PG. et al. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010; 116: 529-536.
• 24 Meltzer ME, Doggen CJM, de Groot PG. et al. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009; 145: 121-127.
• 25 Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
• 26 Undas A, Topor-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn 2009; 119: 354-359.
• 27 Meltzer ME, Doggen CJ, de Groot PG. et al. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007; 14: 242-248.
• 28 Undas A, Plicner D, Stepien E. et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost 2007; 05: 1988-1990.
• 29 He S, Bark N, Wang H. et al. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis. J Cardiovasc Pharmacol 2009; 53: 24-29.
• 30 Guimarares AH, de Bruijne EL, Lisman T. et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-120.
• 31 Zabczyk M, Majewski J, Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Med Wewn 2011; 121: 400-407.
• 32 Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 2011; 121: 110-119.
• 33 Szuldrzynski K, Zalewski J, Machnik A. et al. Elevated levels of 8-iso-prostagland-in F2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol Arch Med Wewn 2010; 120: 19-24.
• 34 Carter AM, Cymbalista CM, Spector TD. et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-2789.
• 35 Collet JP, Montalescot G, Lesty C. et al. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90: 428-434.
• 36 Kwasny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res 2010; 126: e11-16.